European Commission approves use of Stelara in paediatric patients with plaque psoriasis. Johnson & Johnson
Related news and insights
Novartis,has announced the FDA has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the US. The Cosentyx clinical profile is supported by five years of adult data showing long-lasting efficacy and a consistent safety profile across moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
Merck KGaA has, through one of its subsidiaries, entered into an out-licensing agreement with MoonLake Immunotherapeutics AG, a newly founded clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, for sonelokimab (M 1095).
Amgen has announced that the FDA has accepted for review the supplemental New Drug Application (sNDA) for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.